Alberta Investment Management Corp raised its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 62.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,199 shares of the medical research company's stock after buying an additional 19,218 shares during the quarter. Alberta Investment Management Corp's holdings in Natera were worth $7,099,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. HighPoint Advisor Group LLC grew its holdings in Natera by 30.8% during the first quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after purchasing an additional 468 shares during the period. Amalgamated Bank increased its position in shares of Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after acquiring an additional 740 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after acquiring an additional 207 shares in the last quarter. Teza Capital Management LLC acquired a new stake in shares of Natera during the fourth quarter worth $221,000. Finally, Asset Management One Co. Ltd. bought a new stake in Natera in the 1st quarter valued at $6,753,000. Institutional investors own 99.90% of the company's stock.
Natera Price Performance
NTRA stock traded up $1.99 during midday trading on Monday, reaching $136.57. 1,354,086 shares of the company were exchanged, compared to its average volume of 1,260,657. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The firm has a market capitalization of $18.65 billion, a price-to-earnings ratio of -92.90 and a beta of 1.76. The business has a 50-day moving average price of $157.16 and a two-hundred day moving average price of $155.69.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.56) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.
Insider Transactions at Natera
In related news, CEO Steven Leonard Chapman sold 6,092 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $139.81, for a total value of $851,722.52. Following the completion of the sale, the chief executive officer directly owned 169,400 shares in the company, valued at $23,683,814. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John Fesko sold 1,710 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $139.81, for a total value of $239,075.10. Following the completion of the sale, the insider owned 151,750 shares of the company's stock, valued at $21,216,167.50. This trade represents a 1.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,936 shares of company stock valued at $7,483,846. 7.60% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts have issued reports on NTRA shares. Barclays lifted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday, July 28th. Piper Sandler raised their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $183.76.
Check Out Our Latest Research Report on Natera
About Natera
(
Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories

Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.